MERZ-AESTHETICS
5.11.2020 09:32:12 CET | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced the presentation of data from its medical aesthetics portfolio at the 18th edition of the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place virtually as “AMWC Global 2020, The Virtual Edition”, to be held from Thursday, November 5 to Saturday, November 7, 2020. Merz Aesthetics is an elite sponsor of the global industry congress.
“We are proud to continue our commitment to the medical aesthetics industry by sponsoring this virtual meeting. We are looking forward to sharing data on the Merz Aesthetics portfolio, engage with our customers and partners and present Merz Aesthetics in a new innovative format. It’s time to think differently to keep the momentum of the industry,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics.
In addition to the presentations listed below, Merz Aesthetics is sponsoring two symposium events to be held over the course of the meeting and led by renowned medical aesthetic experts:
“The Skin You Are In – Collagen Expert Session” to be held on Friday, November 6, 15:15h – 16:15h CET. The session will include injection videos and insights from renowned international experts:
- Dr. Gabriela Casabona – Aesthetic Physician, Spain
- Dr. Jani van Loghem – Aesthetic Physician, The Netherlands
- Professor Yana A. Yutskovskaya – Dermatologist, Russia
“conFRONT every LINE! – Upper Face Rejuvenation” to be held on Saturday, November 7, 12:30h – 13:30h CET. The session will include injection videos and insights from renowned international experts:
- Dr. Tatjana Pavicic – Dermatologist, Germany
- Dr. Thomas Rappl – Dermatologist, Austria
Oral Presentations
Gabriela Casabona: ‘CaHA as a Biostimulator’ (Evolution of Regenerative Aesthetics Where are We Now Session); Thursday, November 5, 13:30-15:30h CET, AMWC Stream 2*
Dr. Carla Pecora: ‘Botulinum Toxin Injection: Customized Eyebrow Reshape and Positioning, with an Individualized Approach’ (Forehead Treatment and Importance of the Eyebrow Line Session); Thursday, November 5, 16:30-18:30h CET, AMWC Stream 1*
Dr. Daria Voropai: ‘Midface Dilemmas: How Individual Approaches Require a Multiple Tissue Plane Approach and How Ultrasound, Tactile Feedback, Visual Cues Help Us to Achieve This’ (Cheeks: Fillers, Threads of Both? Session); Friday, November 6, 16:30-18:30h CET, AMWC Stream 2 *
Dr. Kate Goldie: ‘Redefining the Art of the Lip’ (Lips and Perioral Rejuvenation Session); Saturday, November 7th, 14:00-16:00h CET, AMWC Stream 2 *
Virtual E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress.
Botulinum Toxin
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. Martina Kerscher, MD - Germany, Sabrina Fabi, MD – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, Dr. med – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
- Decreased Therapeutic Effect Over Time Amongst Botulinum Toxin Type A Agents. Rashid Kazerooni – Merz North America, USA.
- Neurotoxin Impurities: A Review of Threats to Efficacy. Je-Young Park, MD - USA, Owen Sunga, MD, MSc – Singapore, Rungsima Wanitphakdeedecha, MD, MA, MSc – Thailand, Jürgen Frevert, PhD - Germany.
Belotero®
- Safety of Cohesive Polydensified Matrix Cross-Linked Hyaluronic Acid Volumizing Gel in Temporal Hollows and Cheeks: A Prospective, Open-Label, Post-Market Study. Tatjana Pavicic, MD –Germany; Gerhard Sattler, MD – Germany, Welf Prager, MD – Germany, Tanja Fischer, MD PhD – Germany, Gerd Gauglitz, MD – Germany, Matthias Hofmann, PhD - Germany; Hanna Dersch – Germany; Shahbaz Riaz, PharmD – USA, Martina Kerscher, MD – Germany.
- Hydration Effect of a Revitalizing CPM® Cross-Linked Hyaluronic Acid Gel Containing Glycerol. Kay Marquardt, Sabine Falk, Matthias Hofmann, Jeannette Simon, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany.
Radiesse®
- CaHA microspheres remodel collagen networks leading to improved skin quality and reveal new treatment possibilities. Gabriela Casabona, MD – Spain, Bartosch Nowag, Daniela Schäfer, Davide Greco, Thomas Hengl – all Merz Pharmaceuticals GmbH, Germany
- Combination of Calcium Hydroxylapatite Diluted with Normal Saline and Microfocused Ultrasound with Visualization for Skin Tightening. Yana Alexandrovna Yutskovskaya, MD - Russia, Anna Daniilovna Sergeeva, MD – Russia, Evgeniya Altarovna Kogan, MD PhD – Russia.*
Ultherapy®
- Optimizing Patient Outcomes through a Customized Approach of Microfocused Ultrasound with Visualization Treatments: Consensus Guidelines from an Expert Panel. Sabrina G. Fabi, MD - USA, John Joseph, MD - USA, Julia Sevi, MD PhD - UK, Jeremy B. Green, MD - USA, Jennifer Deaver Peterson, MD – USA.
*Merz-supported Investigator Initiated Trial
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
